Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

April 23, 2020

Elicera Therapeutics announced today that six of 12 planned patients have been treated in the ongoing phase I/II study in the treatment of neuroendocrine tumors. ELC-100 has so far not shown any serious side effects in the two different dose groups that have been treated and therefore the Data Safety Monitoring Board (DSMB)) has approved that the next dose group of a total of three patients can also start treatment with ELC-100.

Download attachment (pdf)
< Back to press releases